Brainstorm Cell Therapeutics(BCLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCLI Brainstorm Cell Therapeutics

Pre-Market Trading 12-23 04:29:16 EST

2.28

+0.20

+9.62%

High2.45	Low2.20	Vol197.81K
Open2.23	D1 Closing2.08	Amplitude11.97%
Mkt Cap13.00M	Tradable Cap10.62M	Total Shares5.70M
T/O456.13K	T/O Rate4.25%	Tradable Shares4.66M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BCLI","market":"US","secType":"STK","nameCN":"Brainstorm Cell Therapeutics","latestPrice":2.28,"timestamp":1734728400000,"preClose":2.08,"halted":0,"volume":197807,"delay":0,"floatShares":4659200,"shares":5703426,"eps":-3.309024,"marketStatus":"Pre-Market Trading","change":0.2,"latestTime":"12-23 04:29:16 EST","open":2.23,"high":2.4499,"low":2.201,"amount":456131.251606,"amplitude":0.119663,"askPrice":2.85,"askSize":100,"bidPrice":1.91,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.309024,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1734964200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1052452800000,"exchange":"NASDAQ","adjPreClose":2.28,"postHourTrading":{"tag":"盘后","latestPrice":2.29,"preClose":2.28,"latestTime":"19:54 EST","volume":15067,"amount":34501.4,"timestamp":1734742460822},"volumeRatio":1.0503208040982102,"impliedVol":0.6467,"impliedVolPercentile":0.2813},"requestUrl":"/m/hq/s/BCLI/tweets","defaultTab":"tweets","newsList":[{"id":"2491179579","title":"Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD) and Brainstorm Cell Therapeutics (BCLI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491179579","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491179579?lang=en_us&edition=fundamental","pubTime":"2024-12-15 23:50","pubTimestamp":1734277821,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Opus Genetics (IRD – Research Report) and Brainstorm...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-opus-genetics-ird-and-brainstorm-cell-therapeutics-bcli?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-opus-genetics-ird-and-brainstorm-cell-therapeutics-bcli?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCLI","HCSG","IRD","BK4137","BK4007"],"gpt_icon":0},{"id":"2490672544","title":"Brainstorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2490672544","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490672544?lang=en_us&edition=fundamental","pubTime":"2024-12-09 20:00","pubTimestamp":1733745604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nTUA9TXXZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCLI"],"gpt_icon":0},{"id":"2490229357","title":"BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2490229357","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490229357?lang=en_us&edition=fundamental","pubTime":"2024-12-09 20:00","pubTimestamp":1733745600,"startTime":"0","endTime":"0","summary":"Call Scheduled for December 30, 2024, at 8:30 AM ET; Additionally, Key Opinion Leader Webinar on ALS Advancements to Take Place on December 11, 2024. NEW YORK, Dec. 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today thatit will hold a conference call and webcast on December 30, 2024, at 8:30 a.m. Eastern Time.AboutBrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative therapies for debilitating neurodegenerative diseases, leveraging both autologous and allogeneic platforms. The Company holds exclusive worldwide licensing rights for the NurOwn technology platform, which produces autologous MSC-NTF cells. These cells have received Orphan Drug designation from the U.S. Food and Drug Administration  and the European Medicines Agency  for amyotrophic lateral sclerosis . BrainStorm is currently planning the launch of a confirmatory Pha","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OOkutZzmduEoM.09cK39MQ--~B/aD0xMzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c3251351433584be7e825803dfe4a8a0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OOkutZzmduEoM.09cK39MQ--~B/aD0xMzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c3251351433584be7e825803dfe4a8a0"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/brainstorm-cell-therapeutics-host-investor-120000320.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brainstorm-cell-therapeutics-host-investor-120000320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4516","BK4585","KOL","LENZ","BK4218","BK4181","BK4127","LU0320765646.SGD","LU2089283258.USD","LU0098860793.USD","LU2111349929.HKD","PHH","LU0006306889.USD","LU0158827948.USD","IE00BZ1G4Q59.USD","LU2271345857.HKD","LU0106261372.USD","LU1162221912.USD","HST","IE00BKVL7J92.USD","LU1989772840.SGD","LU2028103732.USD","BCLI","LU1989772923.USD","LU1668664300.SGD","LU1720051108.HKD","LU2089284900.SGD","LU0267386448.USD","WRD","LU0158827781.USD","LU2357305700.SGD","LU1074936037.SGD","LU0106831901.USD","BK4588","LU2023251221.USD","BK4504","BK4534","LU1363072403.SGD","LU0971096721.USD","LU1548497426.USD","BK4139","LU0314104364.USD","LU1720051017.SGD","LU0225283273.USD","BK4581"],"gpt_icon":0},{"id":"2488916515","title":"BRIEF-Brainstorm Strengthens Exosome Patent Portfolio, Receives Notice Of Allowance For U.S. Patent Covering Its Platform Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2488916515","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488916515?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:07","pubTimestamp":1733227641,"startTime":"0","endTime":"0","summary":"Dec 3 (Reuters) - Brainstorm Cell Therapeutics   :   * BRAINSTORM: STRENGTHENS EXOSOME PATENT PORTFOLIO, RECEIVES NOTICE OF ALLOWANCE FOR U.S. PATENT COVERING ITS PLATFORM TECHNOLOGYSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCLI"],"gpt_icon":0},{"id":"2488812919","title":"BrainStorm receives Notice of Allowance for patent on exosome technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2488812919","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488812919?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:05","pubTimestamp":1733227537,"startTime":"0","endTime":"0","summary":"BrainStorm (BCLI) Cell Therapeutics announced that it has received Notice of Allowance from the U.S. Patent & Trademark Office for patent applicati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/brainstorm-receives-notice-of-allowance-for-patent-on-exosome-technology?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/brainstorm-receives-notice-of-allowance-for-patent-on-exosome-technology?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCLI"],"gpt_icon":0},{"id":"2488916373","title":"Brainstorm: Strengthens Exosome Patent Portfolio, Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2488916373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488916373?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:05","pubTimestamp":1733227504,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nFWN3N31AK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCLI"],"gpt_icon":0},{"id":"2488367919","title":"BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2488367919","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488367919?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:00","pubTimestamp":1733227200,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec. 3, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it has received Notice of Allowance from the U.S. Patent & Trademark Office  for patent application 16/981,757 which covers its proprietary exosome technology.\"This patent strengthens BrainStorm's intellectual property portfolio and highlights our commitment to advancing novel technologies for respiratory and neurodegenerative diseases,\" said Chaim Lebovits, BrainStorm's President and Chief Executive Officer. \"Our primary focus continues to be development of NurOwn for ALS as we prepare to initiate a Phase 3b registrational trial. We are seeking additional ways to unlock value from our assets and are pursuing strategic collaborations for the exosome platform.\". BrainStorm Cell Therapeutics Inc. is a leading developer of innovative therapies for debilitating neurodegenerative diseases, leveraging both autologo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OOkutZzmduEoM.09cK39MQ--~B/aD0xMzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c3251351433584be7e825803dfe4a8a0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OOkutZzmduEoM.09cK39MQ--~B/aD0xMzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c3251351433584be7e825803dfe4a8a0"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/brainstorm-strengthens-exosome-patent-portfolio-120000643.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brainstorm-strengthens-exosome-patent-portfolio-120000643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0225283273.USD","WRD","BK4139","LU0158827948.USD","LU2357305700.SGD","LU1162221912.USD","LU0106831901.USD","IE00BZ1G4Q59.USD","LU1989772840.SGD","BCLI","BK4516","LU2028103732.USD","BK4127","LU1989772923.USD","BK4581","LU0098860793.USD","LU1720051108.HKD","BK4588","LU0971096721.USD","LU1720051017.SGD","LU2089284900.SGD","BK4504","LU0320765646.SGD","LU2023251221.USD","BK4534","LU2111349929.HKD","LU1668664300.SGD","LU1363072403.SGD","LU0314104364.USD","LU0106261372.USD","IE00BKVL7J92.USD","LU0267386448.USD","LU2089283258.USD","LU0006306889.USD","BK4585","LU1548497426.USD","LU1074936037.SGD","LU2271345857.HKD","LU0158827781.USD"],"gpt_icon":0},{"id":"2488968186","title":"BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2488968186","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488968186?lang=en_us&edition=fundamental","pubTime":"2024-12-02 20:00","pubTimestamp":1733140800,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec. 2, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will host a key opinion leader  webinar on Wednesday, December 11, 2024 at 10:00 AM ET. To register, click here.The webinar will feature Dr. Terry Heiman-Patterson, a KOL from the Lewis Katz School of Medicine at Temple University, who will discuss the current treatment landscape and advances for patients with amyotrophic lateral sclerosis . Dr. Heiman-Patterson will be joined by BrainStorm's management team, who will share updates on the company's planned Phase 3b registrational clinical trial, NurOwn, and future development plans.Successful completion of the randomized portion  of the Phase 3b trial is expected to support a Biologic License Application  for NurOwn.A live Q&A session will follow the formal presentations.BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adul","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OOkutZzmduEoM.09cK39MQ--~B/aD0xMzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c3251351433584be7e825803dfe4a8a0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OOkutZzmduEoM.09cK39MQ--~B/aD0xMzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c3251351433584be7e825803dfe4a8a0"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/brainstorm-cell-therapeutics-host-kol-120000918.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brainstorm-cell-therapeutics-host-kol-120000918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","WRD","KOL","BCLI","BK4139","LENZ","BK4181","HST","BK4585","BK4218"],"gpt_icon":0},{"id":"2483337118","title":"Brainstorm Cell Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483337118","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483337118?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:10","pubTimestamp":1731679844,"startTime":"0","endTime":"0","summary":"Brainstorm Cell Therapeutics Inc reports results for the quarter ended September 30 - Earnings SummaryBrainstorm Cell Therapeutics Inc BCLI.OQ reported a quarterly adjusted loss of 51 cents per share ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nL8N3MM1C6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCLI"],"gpt_icon":0},{"id":"2483356273","title":"Brainstorm Cell Q3 2024 GAAP EPS $(0.51) Beats $(0.57) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483356273","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483356273?lang=en_us&edition=fundamental","pubTime":"2024-11-15 06:23","pubTimestamp":1731623025,"startTime":"0","endTime":"0","summary":"Brainstorm Cell (NASDAQ:BCLI) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.57) by 10.53 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41993879/brainstorm-cell-q3-2024-gaap-eps-0-51-beats-0-57-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Brainstorm Cell Q3 2024 GAAP EPS $(0.51) Beats $(0.57) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCLI"],"gpt_icon":0},{"id":"2483583243","title":"Brainstorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483583243","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483583243?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:30","pubTimestamp":1731619803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA9HJXWP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCLI"],"gpt_icon":0},{"id":"2483838453","title":"Brainstorm Cell Therapeutics Inc  expected to post a loss of 57 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2483838453","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483838453?lang=en_us&edition=fundamental","pubTime":"2024-11-13 23:42","pubTimestamp":1731512569,"startTime":"0","endTime":"0","summary":"Brainstorm Cell Therapeutics Inc  expected to post a loss of57cents a share - Earnings Preview Brainstorm Cell Therapeutics Inc BCLI.OQ BCLI.O is expected to show no change in quarterly revenue when i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL8N3MK270:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCLI"],"gpt_icon":0},{"id":"2482202494","title":"BrainStorm enters MOU with Pluri to support NurOwn trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2482202494","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482202494?lang=en_us&edition=fundamental","pubTime":"2024-11-11 19:25","pubTimestamp":1731324312,"startTime":"0","endTime":"0","summary":"BrainStorm (BCLI) announced that it has entered into a memorandum of understanding, or MOU, with Pluri (PLUR) through its wholly owned subsidiary t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/brainstorm-enters-mou-with-pluri-to-support-nurown-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/brainstorm-enters-mou-with-pluri-to-support-nurown-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLUR","BK4139","BCLI"],"gpt_icon":0},{"id":"2482620123","title":"Brainstorm Cell Therapeutics Inc - Pluri to Provide Gmp-Compliant Manufacturing of Nurown in Israel","url":"https://stock-news.laohu8.com/highlight/detail?id=2482620123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482620123?lang=en_us&edition=fundamental","pubTime":"2024-11-11 19:00","pubTimestamp":1731322809,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUA1DKRX9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCLI"],"gpt_icon":0},{"id":"2482202849","title":"BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2482202849","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482202849?lang=en_us&edition=fundamental","pubTime":"2024-11-11 19:00","pubTimestamp":1731322800,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov. 11, 2024 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. , a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding  with Pluri Inc.  through its wholly owned subsidiary , an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis . This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facility upon finalizing the binding definitive agreement.The Phase 3b trial has been designed to enroll up to approximately 200 participants with ALS. It will be conducted in two parts: In Part A, participants will receive 3 doses of NurOwn or placebo for 24 weeks. This will be followed by an open label period, during which patients from both arms will receive 3 doses NurOwn for another 24","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OOkutZzmduEoM.09cK39MQ--~B/aD0xMzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c3251351433584be7e825803dfe4a8a0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OOkutZzmduEoM.09cK39MQ--~B/aD0xMzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c3251351433584be7e825803dfe4a8a0"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/brainstorm-cell-therapeutics-pluri-partner-110000497.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brainstorm-cell-therapeutics-pluri-partner-110000497.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PLUR","SPA","LENZ","WRD","BCLI"],"gpt_icon":0},{"id":"2480881015","title":"Brainstorm Cell Therapeutics Inc    expected to post a loss of 57 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2480881015","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480881015?lang=en_us&edition=fundamental","pubTime":"2024-11-01 22:05","pubTimestamp":1730469952,"startTime":"0","endTime":"0","summary":"* Brainstorm Cell Therapeutics Inc     is expected to show no change in quarterly revenue when it reports  results on November 5 (estimated) for the period ending September 30 2024   *    * LSEG's mea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Brainstorm Cell Therapeutics Inc    expected to post a loss of 57 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCLI"],"gpt_icon":0},{"id":"2479272795","title":"BRIEF-Brainstorm Cell Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2479272795","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479272795?lang=en_us&edition=fundamental","pubTime":"2024-10-30 18:49","pubTimestamp":1730285368,"startTime":"0","endTime":"0","summary":"Oct 30 (Reuters) - Brainstorm Cell Therapeutics Inc :   * BRAINSTORM CELL THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENTSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","BK4588","LU2210149790.SGD","SQQQ","NQmain","LU2210150020.SGD","MNQmain",".IXIC","BK4112","QLD","PSQ","BK4139","BCLI","NDAQ","TQQQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","QID","BK4585"],"gpt_icon":0},{"id":"2479279692","title":"BrainStorm regains compliance with Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2479279692","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479279692?lang=en_us&edition=fundamental","pubTime":"2024-10-30 18:15","pubTimestamp":1730283342,"startTime":"0","endTime":"0","summary":"BrainStorm (BCLI) announced that the company received written notice from The Nasdaq Stock Market stating that the company has regained compliance ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/brainstorm-regains-compliance-with-nasdaq-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/brainstorm-regains-compliance-with-nasdaq-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BGHQF748.EUR","BK4585","QLD","PSQ","IE00BKPKM429.USD","MNQmain","IE00B64PRP62.GBP","LU2095319765.USD","BCLI","QID","NQmain","NDAQ","SQQQ","TQQQ","IE00B3QW5Z07.USD","BK4588","LU2210149790.SGD","LU2210150020.SGD","BK4139","BK4112",".IXIC"],"gpt_icon":0},{"id":"2479768052","title":"Brainstorm Cell Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2479768052","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479768052?lang=en_us&edition=fundamental","pubTime":"2024-10-30 18:00","pubTimestamp":1730282409,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nTUA7YZ5SK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCLI"],"gpt_icon":0},{"id":"2479276571","title":"BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2479276571","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479276571?lang=en_us&edition=fundamental","pubTime":"2024-10-30 18:00","pubTimestamp":1730282400,"startTime":"0","endTime":"0","summary":"NEW YORK, Oct. 30, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of cellular therapies for neurodegenerative diseases, today announced that on October 29, 2024, the Company received written notice from The Nasdaq Stock Market stating that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.Accordingly, the Company's common stock will continue to trade on The Nasdaq Capital Market, subject to the Company's compliance with Nasdaq's continued listing requirements.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OOkutZzmduEoM.09cK39MQ--~B/aD0xMzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c3251351433584be7e825803dfe4a8a0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OOkutZzmduEoM.09cK39MQ--~B/aD0xMzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c3251351433584be7e825803dfe4a8a0"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/brainstorm-cell-therapeutics-regains-compliance-100000048.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brainstorm-cell-therapeutics-regains-compliance-100000048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BGHQF748.EUR","BK4139","LENZ","TQQQ","QID","IE00B64PRP62.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD","QLD",".IXIC","NQmain","MNQmain","BCLI","LU2210149790.SGD","IE00BKPKM429.USD","SQQQ","BK4588","PSQ","BK4112","LU2095319765.USD","BK4585","NDAQ"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.brainstorm-cell.com","stockEarnings":[{"period":"1week","weight":0.5724},{"period":"1month","weight":0.8095},{"period":"3month","weight":-0.374},{"period":"6month","weight":-0.5892},{"period":"1year","weight":-0.2124},{"period":"ytd","weight":-0.4432}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.021118},{"month":2,"riseRate":0.6,"avgChangeRate":0.112895},{"month":3,"riseRate":0.7,"avgChangeRate":0.101961},{"month":4,"riseRate":0.2,"avgChangeRate":-0.074219},{"month":5,"riseRate":0.5,"avgChangeRate":0.093356},{"month":6,"riseRate":0.5,"avgChangeRate":-0.013366},{"month":7,"riseRate":0.7,"avgChangeRate":0.024805},{"month":8,"riseRate":0.1,"avgChangeRate":-0.02799},{"month":9,"riseRate":0.4,"avgChangeRate":-0.088205},{"month":10,"riseRate":0.2,"avgChangeRate":-0.142267},{"month":11,"riseRate":0.272727,"avgChangeRate":-0.013927},{"month":12,"riseRate":0.636364,"avgChangeRate":0.100252}],"exchange":"NASDAQ","name":"Brainstorm Cell Therapeutics","nameEN":"Brainstorm Cell Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Brainstorm Cell Therapeutics(BCLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Brainstorm Cell Therapeutics(BCLI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Brainstorm Cell Therapeutics,BCLI,Brainstorm Cell Therapeutics股票,Brainstorm Cell Therapeutics股票老虎,Brainstorm Cell Therapeutics股票老虎国际,Brainstorm Cell Therapeutics行情,Brainstorm Cell Therapeutics股票行情,Brainstorm Cell Therapeutics股价,Brainstorm Cell Therapeutics股市,Brainstorm Cell Therapeutics股票价格,Brainstorm Cell Therapeutics股票交易,Brainstorm Cell Therapeutics股票购买,Brainstorm Cell Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Brainstorm Cell Therapeutics(BCLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Brainstorm Cell Therapeutics(BCLI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction